Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056170 | 1.00 | GRM2 (0.46) | GRM2PRMT1CYP2C9GRM3ATM | |
| SCHEMBL31537531 | 1.00 | GRM2 (0.46) | GRM2PRMT1CYP2C9GRM3ATM | |
| SCHEMBL3471771 | 0.83 | KIF11 (0.48) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL3053149 | 0.81 | ATM (0.39) | GRM2PRMT1CYP2C9GRM3ATM | |
| SCHEMBL14459215 | 0.81 | KIF11 (0.47) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL14459222 | 0.79 | KIF11 (0.51) | KIF11 | |
| SCHEMBL14459219 | 0.79 | KIF11 (0.45) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL11377698 | 0.78 | PRMT1 (0.45) | GRM2PRMT1CYP2C9GRM3ATM | |
| SCHEMBL4384080 | 0.76 | PRMT1 (0.48) | PRMT1CYP2C9ATML3MBTL1LMNA | |
| SCHEMBL3053147 | 0.75 | PRMT1 (0.43) | GRM2PRMT1CYP2C9GRM3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025079064-A1 | INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS | PEPTICOM LTD. (IL) | 2025-04-17 | — | — | WO | disclosed |
| US-7745392-B2 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | NITTO DENKO CORPORATION (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20070078078-A1 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
| WO-2007038169-A2 | MULTI-VALENT GUANIDINIUM COMPOUNDS FOR MOLECULAR TRANSLOCATION ACROSS CELLULAR MEMBRANES AND EPITHELIAL TISSUES | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | WO | disclosed |
| US-4267344-A | 3-PENTA/ALKOXY/BENZYL-; -XANTHYL-, -THIOXANTHYL-, OR -SELENOXANTHYLOXAZOLIDINE-2,5-DIONES | PROTEINKEMISK INSTITUT. TILKNYTTET AKADEMIET FOR DE TEKNISKE VIDENSKABER (DK) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078078-A1 | Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues | GLS, FABP2, GOLIM4 | GRM2 442/4885PRMT1 824/4885CYP2C9 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.